A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination
Healthy participants aged 18-59 years
Capable of providing informed consent in person
Willing and able to comply with all clinical trial requirements
Axillary temperature >37.0°C on enrollment day *
Received any influenza vaccine within the past 6 months or plans to receive other influenza vaccines during the trial
History of laboratory-confirmed influenza (by clinical, serological, or microbiological methods) within the past 6 months
Female participants of childbearing potential with positive urine pregnancy test, currently breastfeeding, or planning pregnancy within 6 months
Changchun BCHT Biotechnology Co.
Lead sponsor
Hubei Provincial Center for Disease Control and Prevention
Collaborator
Center for Disease Control and Prevention, Fujian
Collaborator
Zhejiang Provincial Center for Disease Control and Prevention
Collaborator